{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:37:13Z","timestamp":1785332233402,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psycho-Oncology"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic>: Knowledge of sleep aid use is limited despite the high prevalence of insomnia among women before, during, and following breast cancer adjuvant chemotherapy treatments (CTX). This study's purpose was to (1) determine the frequency and characteristics of participants taking sleep aid(s); (2) identify the frequency and percentage of sleep aid use by category (prescription sedative\/hypnotics, prescription anti\u2010depressants, prescription analgesics, prescription anti\u2010emetics, over\u2010the\u2010counter (OTC) analgesics, OTC cold\/flu\/sinus, OTC sleep, alcohol, and herbal supplements); and (3) compare sleep aid use by category in the experimental and control groups within a randomized\u2010controlled clinical trial (RCT).<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>: Longitudinal, descriptive, secondary RCT data analysis of women (<jats:italic>n<\/jats:italic>=219) receiving out\u2010patient CTX, and at 30, 60, and 90 days following the last CTX and 1 year following CTX1. Participants recorded daily sleep aid use on a Sleep Diary. Analyses included descriptives, chi\u2010square, and RM\u2010ANOVA.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: Approximately 20% of participants took at least one sleep aid before CTX1; usage decreased over time (12\u201318%); a second sleep aid was used infrequently. Prescription sedative\/hypnotics (46%) and OTC analgesics (24%) were used most frequently. OTC sleep aids were most commonly used as a second aid. Prescription sedative\/hypnotics [<jats:italic>F<\/jats:italic>(7,211)=4.26, <jats:italic>p<\/jats:italic>=0.00] and OTC analgesics [<jats:italic>F<\/jats:italic>(7,211)=2.38, <jats:italic>p<\/jats:italic>=0.023] use decreased significantly over time.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>: Results reflect the natural course of CTX, recovery, and healing. Comprehensive screening for sleep\u2013wake disturbances and sleep aid use may lead to a better understanding of the risks and benefits of pharmacologic and non\u2010pharmacologic interventions, and ultimately lead to selection of the safest and most effective treatment. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/pon.1756","type":"journal-article","created":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T23:03:47Z","timestamp":1273014227000},"page":"321-325","source":"Crossref","is-referenced-by-count":33,"title":["Sleep aid use during and following breast cancer adjuvant chemotherapy"],"prefix":"10.1002","volume":"20","author":[{"given":"Tiffany A.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dizona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"e_1_2_6_2_2","article-title":"Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center\u2013Community Clinical Oncology Program","author":"Palesh OG","year":"2009","journal-title":"Journal of Clinical Oncology."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3248"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/24.5.583"},{"key":"e_1_2_6_5_2","volume-title":"International Classification of Sleep Disorders: Diagnostic and Coding Manual","author":"American Academy of Sleep Medicine","year":"2005"},{"issue":"5","key":"e_1_2_6_6_2","first-page":"S7","article-title":"Insomnia: Definition, prevalence, etiology, and consequences","volume":"3","author":"Roth T","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"e_1_2_6_7_2","unstructured":"National Sleep Foundation. Summary of Findings.2007. Retrieved fromhttp:\/\/www.sleepfoundation.org\/sites\/default\/files\/Summary_Of_Findings%20\u2010%20FINAL.pdf."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197911)44:5<1919::AID-CNCR2820440555>3.0.CO;2-T"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-8343(85)90051-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.03.032"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.548"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951505050042"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-199904000-00006"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.09.010"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1438"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8306"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471264385.wei0914"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1188\/09.ONF.563-570"},{"key":"e_1_2_6_20_2","unstructured":"AmbienCR. Ambien CR side effects. Retrieved on December 1 2009 fromhttp:\/\/www.ambiencr.com\/using\u2010ambine\/ambien\u2010cr\u2010side\u2010effects.aspx."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735404265003"}],"container-title":["Psycho-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpon.1756","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpon.1756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pon.1756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T09:42:41Z","timestamp":1700559761000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pon.1756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1002\/pon.1756"],"URL":"https:\/\/doi.org\/10.1002\/pon.1756","archive":["Portico"],"relation":{},"ISSN":["1057-9249","1099-1611"],"issn-type":[{"value":"1057-9249","type":"print"},{"value":"1099-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]}}}